Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use

Authors: Novak, Suzanne1; Melkonian, Arthur K.2; Patel, Pankaj A.3; Kleinman, Nathan L.4; Joseph-Ridge, Nancy3; Brook, Richard A.5

Source: Current Medical Research and Opinion, Volume 23, Number 3, March 2007 , pp. 623-630(8)

Publisher: Informa Healthcare

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective: A cohort of employees with gout were compared to those without to evaluate the differences in prevalence of disorders associated with metabolic syndrome (both those considered underlying and those associated with end-stage morbidity and mortality) as well as the cost of annual medical services (AMS) required for treatment of these conditions.

Methods: Employees with gout were identified by International Classification of Diseases-9 (ICD-9) code during the calendar years of 2001-2004 and compared to propensity-score matched employees without gout using the Human Capital Management Services Research Reference Database. T-tests were then used to compare prevalence and average AMS of comorbid disorders defined from Agency for Healthcare and Research Quality (AHRQ) diagnostic categories.

Results: 'Hyperlipidemia', 'essential hypertension', and 'diabetes mellitus without complications' ranked in the top 10 categories of mean number of AMS for employees with gout using AHRQ specific categories; the values were higher than found for those without gout (all p < 0.0001). 'Essential hypertension', 'hyperlipidemia', 'diabetes mellitus without complications', and 'coronary atherosclerosis' showed an approximate 2:1 prevalence ratio for employees with gout over those without (p ≤ 0.05). Main study limitations include the small number of subjects with gout, retrospective study design, and possible miscoding and/or non-coding of individuals with the studied disorders.

Conclusion: These results support the continued need for patients with gout and their clinicians to be aware of the possibility of the increased risk of associated metabolic syndrome and related comorbidities in these individuals, emphasizing the need for prevention when possible and treatment when necessary.

Keywords: EPIDEMIOLOGY; GOUT; HYPERURICEMIA; METABOLIC SYNDROME

Document Type: Research article

DOI: 10.1185/030079906X167651

Affiliations: 1: Pharmacy Practice, University of Texas at Austin, Austin, TX, USA 2: Human Capital Management Services, Yereven, Armenia 3: TAP Pharmaceutical Products, Inc, Lake Forest, IL, USA 4: Human Capital Management Services, Cheyenne, WY, USA 5: The JeSTARx Group, Newfoundland, NJ, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A